2006-10-17

Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent


New York (ots/PRNewswire) -

Pfizer said today that the Austrian Patent Office has ruled that aclaim in the company's basic patent covering the use of atorvastatin,the active ingredient in Lipitor, would be infringed by genericmanufacturer Ranbaxy. Ranbaxy can appeal the ruling, but the patentwill remain in effect during the appeals process. Lipitor is sold inAustria under the brand name Sortis.

The decision will allow Pfizer to take further legal action toprevent Ranbaxy from launching a competitor product before theexpiration of Lipitor's basic patent on November 7, 2011.

"The decision by the Austrian Patent Office is yet anotheraffirmation of the strength of the intellectual property behind thisimportant medical breakthrough," said Pfizer general counsel AllenWaxman. "The ruling reinforces the fundamental principle that patentlaws exist to support and encourage medical innovators, not underminethem."

Pfizer said it will continue to vigorously contest challenges toits Lipitor patents around the world.

Web site: http://www.pfizer.com

ots Originaltext: Pfizer Inc.Im Internet recherchierbar: http://www.presseportal.de

Contact:Bryant Haskins, +1-212-733-8719, for Pfizer; Photo: A free corporatelogo to accompany this story is available immediately via Wieck PhotoDatabase to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call +1-972-392-0888. Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html/

Pfizer Inc.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent

Medizin-News